Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.3 NOK | -1.79% | +0.56% | +55.00% |
Apr. 26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company sustains low margins.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 260.76 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Fishing & Farming
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+55.00% | 566M | B- | ||
+12.78% | 3.29B | B | ||
-95.58% | 1.61B | - | C+ | |
-0.48% | 1.61B | C | ||
-2.37% | 1.25B | D+ | ||
-2.40% | 1.22B | B | ||
-.--% | 1.22B | - | - | |
-11.54% | 1.21B | - | - | |
-10.44% | 1.2B | - | ||
0.00% | 1.19B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AKBM Stock
- Ratings Aker BioMarine